Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Amgen
(NQ:
AMGN
)
325.09
+0.47 (+0.14%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amgen
< Previous
1
2
3
4
5
6
7
8
9
...
46
47
Next >
Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade
October 14, 2024
The analyst is closely watching MariTide, a potential monthly injection to treat obesity.
Via
Investor's Business Daily
In-Depth Examination Of 11 Analyst Recommendations For Amgen
October 14, 2024
Via
Benzinga
Blue Skies, New Highs Remain Disciplined And Do Not Chase Extended Ideas
October 13, 2024
It is Fall clean up time. Sell lagging and sagging companies.
Via
Talk Markets
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
October 11, 2024
The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.
Via
Benzinga
2 Top Dividend Stocks to Buy Hand Over Fist Right Now
October 11, 2024
Income stocks can be wise additions to your portfolio in any market environment.
Via
The Motley Fool
(AMGN) - Analyzing Amgen's Short Interest
September 30, 2024
Via
Benzinga
Analyst Expectations For Amgen's Future
September 25, 2024
Via
Benzinga
Market Whales and Their Recent Bets on AMGN Options
September 24, 2024
Via
Benzinga
18 Stocks To Buy, 7 To Sell This Earnings Season: Goldman Sachs Calls It 'The Year Of The Stock Picker'
October 10, 2024
Goldman Sachs identifies 18 stocks for potential earnings upside and advises options-based strategies in a volatile market. 10% upside for S&P 500.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Deere, Amgen, Copart And More: CNBC's 'Final Trades'
October 10, 2024
On CNBC's "Halftime Report Final Trades," Jim Lebenthal of Cerity Partners named Deere & Company as his final trade.
Via
Benzinga
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
October 09, 2024
The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential...
Via
Benzinga
What the Options Market Tells Us About Amgen
September 23, 2024
Via
Benzinga
2 Biotech Stocks to Buy Hand Over Fist in October
October 09, 2024
These longtime leading biotech stocks still have plenty of upside ahead.
Via
The Motley Fool
Want to Invest in the Weight Loss Boom? Consider Buying These 2 Stocks
October 08, 2024
Investing in the most popular players in the space isn't the only valid approach.
Via
The Motley Fool
3 Magnificent Dividend Stocks to Buy in October
October 06, 2024
These dividend stocks are great picks as the fall season gets underway.
Via
The Motley Fool
Should You Buy the Dip on This Top Growth Stock?
October 05, 2024
The biotech needs to overcome an issue most drugmakers face at some point.
Via
The Motley Fool
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
October 04, 2024
Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention.
Via
Investor's Business Daily
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
October 03, 2024
Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Federal Judge Rules Amgen Must Face Tax Liability Lawsuit That Alleges Reckless Concealment Of $10.7B Tax Bill
October 02, 2024
Amgen faces a class-action lawsuit over allegations of concealing a $10.7 billion tax dispute with the IRS, with shareholders accusing the company of delaying critical disclosures. A federal judge...
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
AskSlim Market Week - Friday, Sep. 27
September 27, 2024
An analysis and commentary on the financial markets.
Via
Talk Markets
Stock Market Rally Hits Fresh Highs, Fueled By Micron Earnings, China Stimulus: Weekly Review
September 27, 2024
The S&P 500 hit record highs, fueled by Micron and Chinese stimulus.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Taiwan Semiconductor, American Tower, Trane Technologies And A Health Care Stock On CNBC's 'Final Trades'
September 26, 2024
Analyst Stephen Weiss of Short Hills Capital Partners said he still finds Taiwan Semiconductor Manufacturing Company cheap.
Via
Benzinga
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
September 25, 2024
Amgen releases Phase 3 trial data for rocatinlimab and Uplizna, with analysts projecting strong sales despite competition in the atopic dermatitis and myasthenia gravis markets. Attention shifts to...
Via
Benzinga
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases
September 25, 2024
Amgen tested its drug, Uplizna, in generalized myasthenia gravis, a market where Argenx's Vyvgart leads.
Via
Investor's Business Daily
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
September 25, 2024
Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna outperforming expectations in myasthenia gravis, offering less frequent...
Via
Benzinga
Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday?
September 24, 2024
Regeneron filed an appeal after a court's decision, which was issued under seal.
Via
Benzinga
2 Weight-Loss Stocks That Could Rocket Higher This Year
September 24, 2024
Upcoming clinical trial results could push these stocks through the roof before 2024 is finished.
Via
The Motley Fool
Tesla Leads S&P 500 Index, While Biotech Giant Tumbles On Court Ruling
September 23, 2024
The EV giant, once a big S&P 500 laggard in 2024, is now up for the year.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea
September 23, 2024
Eylea is one of Regeneron's biggest moneymakers, and Amgen is looking to knock it off.
Via
Investor's Business Daily
Amgen vs. Viking Therapeutics: What's the Better GLP-1 Stock to Buy?
September 23, 2024
These two stocks could be rivals in the intense GLP-1 space in the future.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
46
47
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.